Granisetron Hydrochloride and Respiratory syncytial virus immune globulin, human Intravenous

• Generic Name: granisetron
• Dosage Forms: n.a.
• Other Brand Names: Kytril, Sustol, Sancuso

Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin.

For prevention of nausea and vomiting associated with highly emetogenic chemotherapy regimens (including an anthracycline plus cyclophosphamide), ASCO recommends a 3-drug antiemetic regimen consisting of an NK1 receptor antagonist (e.g., either oral aprepitant or IV fosaprepitant), a 5-HT3 receptor antagonist (e.g., dolasetron, granisetron, ondansetron, palonosetron), and dexamethasone. ASCO states that fixed-combination netupitant and palonosetron plus dexamethasone is an additional treatment option.

For moderately emetogenic chemotherapy regimens, ASCO recommends a 2-drug antiemetic regimen preferably consisting of palonosetron and dexamethasone. If palonosetron is not available, a first-generation 5-HT3 receptor antagonist (preferably granisetron or ondansetron) may be substituted. Limited evidence suggests that aprepitant may be added to this regimen; in such cases, use of any 5-HT3 receptor antagonist is appropriate.

For chemotherapy regimens with a low emetogenic risk, ASCO recommends administration of a single dose of dexamethasone prior to chemotherapy.

For chemotherapy regimens with minimal emetogenic risk, ASCO states that routine antiemetic administration is not necessary.

Prevention and treatment of postoperative nausea and vomiting.

Routine prophylaxis not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively.

Recommended for patients who, in the clinician’s judgment, must avoid nausea and/or vomiting postoperatively, even when anticipated incidence is low.

Prevention of nausea and vomiting associated with radiation, including total body irradiation and daily fractionated abdominal radiation.

• Generic Name: respiratory syncytial virus immune globulin
• Dosage Forms: n.a.
• Other Brand Names:

Respiratory syncytial virus immune globulin intravenous (RSV-IGIV) belongs to a group of medicines known as immunizing agents. RSV-IGIV is used to prevent infection caused by respiratory syncytial virus (RSV). RSV-IGIV works by giving your body the antibodies it needs to protect it against RSV infection.

RSV infection can cause serious problems, such as pneumonia and bronchitis, which affect the lungs; and in severe cases, even death. These problems are more likely to occur in infants and young children less than 6 months of age with chronic lung disease, those born with heart problems, and those with a history of premature birth.

Onset of RSV activity usually occurs in November and continues through April or early May, with peak activity occurring from late January through mid-February. A good way to help prevent RSV infection is to get RSV-IGIV before the start of the RSV season.

RSV-IGIV is used to prevent serious lower respiratory tract infection caused by the respiratory syncytial virus (RSV) in children less than 24 months of age with breathing problems or a history of premature birth.

RSV-IGIV is to be administered only by or under the supervision of your doctor or other health care professional.